NDA 021658 · Azurity
Alvesco
Ciclesonide · Inhalation
Last checked: Nov 20, 2026Latest source record: Feb 16, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Jan 10, 2008
Approved uses
2
Original approval plus efficacy supplements
Registered trials
81
55 Phase 3, 1 recruiting
FAERS reports
11,143
10,133 serious, 567 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 28, 2025.
ALVESCO is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 12 years of age and older. Limitations of Use : ALVESCO is not indicated for the relief of acute bronchospasm. ALVESCO is not indicated for children under 12 years of age. ALVESCO is an inhaled corticosteroid indicated for maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 12 years of age and older. ( 1 ) Limitations of Use : ALVESCO is not indicated for the relief of acute bronchospasm or in pediatric patients less than 12 years of age. ( 1 )
Mechanism: Ciclesonide is a prodrug that is enzymatically hydrolyzed to a pharmacologically active metabolite, C21-desisobutyryl-ciclesonide (des-ciclesonide or RM1) following oral inhalation. Des-ciclesonide has anti-inflammatory activity with affinity for glucocorticoid receptors that is 120 times greater than the parent compound and 12 times greater than dexamethasone. The clinical significance of these findings is unknown. The precise mechanisms of corticosteroid action in asthma are unknown. Inflammation is recognized as an important component in the pathogenesis of asthma. Corticosteroids have...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 17, 2012 Supplement 6 · Efficacy LabelLetter
- Jan 10, 2008 Original approval · Type 3 - New Dosage Form ReviewPediatric Medical ReviewPediatric Clinical Pharmacology Review
2 products under this application
- ALVESCO · CICLESONIDE 0.16MG/INH · AEROSOL, METERED, INHALATION · Prescription
- ALVESCO · CICLESONIDE 0.08MG/INH · AEROSOL, METERED, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ciclesonide" as an intervention, any sponsor and status, largest first.
- PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -VPivotal-lookingCompleted
Cambridge University Hospitals NHS Foundation TrustAcademic, hospital or other
NCT04870333 · 2,240 participants · Start Feb 19, 2021 · Primary completion Apr 16, 2025
Drug: Niclosamide; Placebo and 4 more · For: Covid19
Sites: Cambridge, United Kingdom; Airdrie, United Kingdom; Birmingham, United Kingdom · 45 sites in all
- Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjects With Moderate To Severe Persistent AsthmaPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00254956 · 1,568 participants · Start Jan 2004 · Primary completion Jun 2005
Drug: ciclesonide (XRP1526) · For: Respiratory Tract Diseases; Respiratory Hypersensitivity; Asthma
Sites: Chilly-Mazarin, France
- Dose Response Study of Inhaled Ciclesonide (Glucocorticosteroid) to Patients With Persistent AsthmaPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00174746 · 1,145 participants · Start Mar 2005 · Primary completion Nov 2005
Drug: AVE2635A · For: Asthma
Sites: Bridgewater, New Jersey
- Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00404547 · 1,121 participants · Start Nov 2006 · Primary completion Apr 2008
Drug: Ciclesonide; Usual Care Inhaled Glucocorticosteroids · For: Asthma
Sites: Abbotsford British Columbia, Canada; Ajax, Canada; Alma, Canada · 186 sites in all
- A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and OlderPivotal-lookingCompleted
Sumitomo Pharma America, Inc.Industry
NCT00953147 · 1,110 participants · Start Aug 2009 · Primary completion Jan 2010
Drug: Ciclesonide HFA 80 mcg; Ciclesonide HFA 160 mcg and 1 more · For: Allergic Rhinitis; Perennial Allergic Rhinitis
Sites: Huntington Beach, California; Los Angeles, California; Mission Viejo, California · 45 sites in all
- A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With AsthmaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00384189 · 1,080 participants · Start Sep 2006 · Primary completion Aug 2007
Drug: Ciclesonide; Placebo and 1 more · For: Asthma
Sites: Plovdiv, Bulgaria; Rousse, Bulgaria; Sofia, Bulgaria · 122 sites in all
- Efficacy and Safety of Ciclesonide in Preschool Children With Asthma (2 to 6 Years) (BY9010/M1-207)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00163449 · 1,000 participants (planned) · Start Nov 2005 · Primary completion Nov 2006
Drug: Ciclesonide; Placebo · For: Asthma
Sites: Campinas - SP, Brazil; Curitiba-PR, Brazil; Paraná, Brazil · 96 sites in all
- A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).Pivotal-lookingCompleted
Sumitomo Pharma America, Inc.Industry
NCT01451541 · 848 participants · Start Oct 2011 · Primary completion Dec 2012
Drug: Ciclesonide nasal aerosol 37 mcg; ciclesonide nasal aerosol 74 mcg and 1 more · For: Perennial Allergic Rhinitis; PAR
Sites: Hot Springs, Arkansas; Little Rock, Arkansas; Costa Mesa, California · 60 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- asthma5,034
- dyspnoea3,973
- wheezing3,021
- cough2,157
- therapeutic product effect incomplete2,118
- loss of personal independence in daily activities1,647
- obstructive airways disorder1,440
- pneumonia1,420
- sleep disorder due to a general medical condition1,275
- productive cough1,195
- drug ineffective1,136
- fatigue1,063
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 5 |
| 2007 | 8 |
| 2008 | 36 |
| 2009 | 71 |
| 2010 | 114 |
| 2011 | 179 |
| 2012 | 201 |
| 2013 | 208 |
| 2014 | 225 |
| 2015 | 293 |
| 2016 | 443 |
| 2017 | 413 |
| 2018 | 600 |
| 2019 | 951 |
| 2020 | 1,306 |
| 2021 | 1,966 |
| 2022 | 893 |
| 2023 | 1,048 |
| 2024 | 884 |
| 2025 | 775 |
| 2026 | 524 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Alvesco (Ciclesonide)
2024 spending
$34.9M
Beneficiaries
88,402
217,395 claims
Per beneficiary
$395
$12.84 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $30,903,953 |
| 2021 | $31,974,256 |
| 2022 | $33,342,211 |
| 2023 | $35,011,917 |
| 2024 | $34,900,989 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ciclesonide.
Reynolds NA, Scott LJ · Drugs 2004 · Clinical Trial, Comparative Study
- PROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT-V).
Humphrey TJL, Dosanjh D, Hiemstra TF, et al. · Trials 2023 · Adaptive Clinical Trial
- Quantitative comparison of different inhaled corticosteroids in the treatment of asthma in children.
Zhu H, Liu H, Sui Z, et al. · Pediatr Res 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2006 · Clinical Trial
- Inhaled ciclesonide in adults hospitalised with COVID-19: a randomised controlled open-label trial (HALT COVID-19).
Brodin D, Tornhammar P, Ueda P, et al. · BMJ Open 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Inhaled corticosteroids for the treatment of COVID-19.
Griesel M, Wagner C, Mikolajewska A, et al. · Cochrane Database Syst Rev 2022 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.